Drugs / MR Vaccine SII
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT04183114 Comparator | Sep → Nov 2019 | congenital rubella syndrome, measles | PT Bio Farma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MR Vaccine SII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04183114 ↗ |
| Modality | Vaccine | “MR Vaccine produced by SII (Already registered in Indonesia)” NCT04183114 ↗ |